Silvercorp Metals Files Application for Hong Kong Stock Exchange Listing and Global Share Offering

Debashish Mukherjee — Tue, 26 May 2026 12:13:00 +0200

Silvercorp Metals Inc. is pleased to announce that it has submitted an application (the “Listing Application”) to the Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) regarding a proposed triple primary listing (the “Listing”) of its common shares (the “Shares”) on the Main Board of the Hong Kong Stock Exchange, alongside a planned global offering (the “Global Offering”) of the Shares.

A redacted version of the draft disclosure document related to the Listing Application is available on the Hong Kong Stock Exchange’s website at www.hkexnews.hk/app/appindex.html and on SEDAR+ under the Company’s profile at www.sedarplus.ca. It will also be filed on EDGAR via Form 6-K at www.sec.gov. This draft disclosure includes new and supplemental information about certain aspects of the Company’s business and financial performance, as required under the Hong Kong Stock Exchange Listing Rules, as well as updated disclosures of information previously provided in filings on SEDAR+ and EDGAR.

There can be no certainty regarding whether or when the Listing or Global Offering will proceed. This announcement does not constitute an offer to sell or a solicitation of an offer to purchase any securities, nor shall any sale, offer, or solicitation occur in any jurisdiction where it would be unlawful.

Regulatory Notice

The Shares to be issued under the Global Offering have not been, and will not be, qualified by way of a prospectus in any Canadian jurisdiction and may not be offered or sold in Canada except under an applicable exemption from prospectus requirements under Canadian securities legislation.

The Shares described herein have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons unless registered under the Securities Act and applicable state laws, or pursuant to an available exemption from such registration requirements.

The Shares will be offered and sold solely outside the United States to non-U.S. persons who are not purchasing for the account or benefit of U.S. persons, in accordance with Regulation S under the Securities Act.

Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO

Debashish Mukherjee — Fri, 09 Jan 2026 06:15:00 +0100

Ribo Life Science Co., Ltd, a pioneer in the development of small interfering RNA (siRNA) therapies, has successfully debuted on the Main Board of the Hong Kong Stock Exchange. This achievement represents an important step forward for the capitalization of China’s biopharmaceutical sector in the siRNA space and brings renewed momentum to the industry.

Through its global initial public offering, Ribo issued 31,610,400 shares at a price of HKD 57.97 per share, generating gross proceeds exceeding HKD 1.8 billion. Investor demand was exceptionally strong, with the Hong Kong public offering oversubscribed by more than 100 times and the international placement receiving 16.7 times subscription. These results highlight robust global investor confidence in both the siRNA therapeutic landscape and Ribo’s technological strength.

The funds raised will provide substantial financial backing for the Company’s core operations and future growth. The offering also secured participation from 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International, Dacheng Fund, and Taikang Life Insurance, underscoring institutional confidence in Ribo’s long-term development strategy.

Dr. Zicai Liang, Founder, Chairman, and Chief Executive Officer of Ribo, stated that the Company’s listing in Hong Kong marks a defining moment in its evolution. He expressed appreciation to global investors for their continued support and emphasized that Ribo will utilize international capital markets to speed up global clinical development and commercialization of its siRNA therapies, enhance its technological platforms, deliver innovative treatments to patients worldwide, and generate long-term value for shareholders.

The net proceeds from the IPO will be primarily allocated to four strategic areas: advancing global multicenter clinical trials for key products; funding preclinical and clinical pipeline development; upgrading siRNA delivery systems and related technology platforms; and strengthening working capital and general corporate operations.

Ribo has established a fully integrated research and development platform supported by proprietary intellectual property. Its proprietary liver-targeting RiboGalSTAR delivery technology has enabled multiple drug candidates to progress into Phase II clinical studies. The Company operates R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, forming a global research network that supports the full drug development process, from discovery through international clinical trials.

The successful listing was jointly sponsored by China International Capital Corporation and Citigroup, whose expertise and support contributed to Ribo’s smooth entry into the public capital markets.

Daily CSR

Silvercorp Metals Files Application for Hong Kong Stock Exchange Listing and Global Share Offering

Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO